Thrombolytic Agents: Biologic Properties and Issues Regarding Products Derived by Recombinant DNA Technology
Fibrin deposition plays a role not only in hemostasis, but also in the inflammatory response, defense mechanisms against bacterial invasion, and wound healing. For this mechanism that is perpetually ready to spring into action, the body pays the price of potential accumulation of fibrin microdeposits which constitute a hazard: thrombosis. Counterbalancing this potential danger is the fibrinolytic system which destroys fibrin deposits. In this respect, fibrin deposition may be considered a fundamental mechanism of injured tissue repair and fibrinolysis (thrombolysis) its physiologic antithesis.
KeywordsFermentation Carbohydrate Mold Aspirin Heparin
Unable to display preview. Download preview PDF.
- 1.Bell WR. Thrombolytic therapy: a comparison between urokinase and streptokinase. Sem Thromb Hemost 1975; 2: 1–13.Google Scholar
- 2.Paoletti R, Sherry S (eds). Thrombosis and urokinase. Academic Press London, 1977; pp. 257.Google Scholar
- 3.Martin M. Streptokinase in chronic arterial disease, C.R.C. Press, Boca Raton, 1982; pp. 196.Google Scholar
- 4.Aoki N (volume ed). Fibrinolysis. Sem Thromb Hemost 1985; 10: 1–107.Google Scholar
- 5.Collen D, Lijnen HR, Verstraete M (eds). Thrombolysis. Biological and therapeutic properties of new thrombolytic agents. Churchill Livingstone, N.Y., 1985; pp. 173.Google Scholar
- 8.Sobel BE, Collen D, Grossbard EB, (eds). Tissue plasminogen activator in thrombolytic therapy. Marcel Dekker, Inc. N.Y./Basel, 1987; pp. 241.Google Scholar
- 10.Liu DT, Goldman H, Gates F. Consideration of the proteins and peptides produced by new technology for use as therapeutics. In: Delivery systems for peptide drugs. NATO ASI series A. Life Sciences 1987; 125: 341–349.Google Scholar
- 11.Gates FT. Regulating new technologies. Pharmaceutical Engineering 1987; 7: 22–25.Google Scholar
- 12.GISSI. Long term effects of intravenous thrombolysis in acute myocardial infarction: Final report of GISSI study. Lancet 1987; 2:871–874.Google Scholar
- 13.ISIS-2 (Second International Study of infarct survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 1787 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2:349–360.Google Scholar
- 14.AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial. Lancet 1988; 1:545–549.Google Scholar
- 15.ASSET Trial Study Group. Trial of Tissue plasminogen activator for mortality reduction in acute myocardial infarction. Lancet 1988; 2:525–530.Google Scholar